Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine
Background: Irritable bowel syndrome (IBS) is a functional gastrointestinal condition marked by chronic bowel pain or discomfort, as well as changes in abdominal motility. Despite its worldwide prevalence and clinical impact, the cause of IBS is unknown. Inflammation could play a fundamental role in...
Saved in:
Main Authors: | Sahar M. El‑Haggar, Sahar K. Hegazy, Sherief M. Abd-Elsalam, Mostafa M. Bahaa |
---|---|
Format: | article |
Language: | EN |
Published: |
Elsevier
2022
|
Subjects: | |
Online Access: | https://doaj.org/article/4ee74657a09b4c18aa2c8a8fc9d5b97d |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effects of pentoxifylline on canine platelet aggregation
by: John M. Thomason, et al.
Published: (2021) -
The role of visceral hypersensitivity in the pathogenesis of irritable bowel syndrome
by: Alina A. Makarova, et al.
Published: (2021) -
Pentoxifylline as a Potential Adjuvant Therapy for COVID-19: Impeding the Burden of the Cytokine Storm
by: Wiktoria Feret, et al.
Published: (2021) -
Phosphodiesterase-4 Inhibition in Psoriasis
by: Milakovic M, et al.
Published: (2021) -
Pentoxifylline therapy for patients with type 2 leprosy reactions: erythema nodosum leprosum in steroid-dependent cases
by: Khairuddin Djawad
Published: (2021)